Rob:
The CML bcr-abl breakpoint
fusion peptide vaccine reported in the Italian study was an earlier
version.
The vaccine in trials at MSKCC
is a more potent version in which "the peptides have been altered to try
to make them more immunogenic," according to an MSKCC research doctor.
I'll know more about the
vaccine's effects on me sometime in June when I get a BMA after the 11th, and
final, injection.
Best Wishes for a Happy Holiday!
Carl
Rob <[EMAIL PROTECTED]> wrote:
To:
[email protected], [email protected], [EMAIL PROTECTED]
From:
Rob <[EMAIL PROTECTED]>
Date: Tue, 13 Dec 2005 22:10:28
-0600
Subject: [CML] CML Vaccine Gives Uneven Results in Control of
Residual Disease
A vaccine against chronic myelogenous leukemia
(CML) has resulted in a molecular response, to varying degrees, in most of
the 21 patients treated in ongoing phase II trials.
In a study
presented during the 47th annual meeting of the American Society of
Hematology that is underway in Atlanta, Georgia, Dr. Monica Bocchia of the
University of Siena, Italy, and colleagues reported interim results with
CML VAX100, a peptide-based vaccine that targets the bcr-abl genes in CML
cells.
Patients in the study had persistent residual disease after
maximal response with imatinib therapy had been achieved. Eighteen
patients completed the initial immunization schedule of six vaccinations
given at two-week intervals. Of these, eight received four booster doses
of the vaccine.
http://cmlsupport.blogspot.com/2005/12/cml-vaccine-gives-uneven-results-in.html
